{"id":385917,"date":"2020-11-20T08:03:13","date_gmt":"2020-11-20T13:03:13","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=385917"},"modified":"2020-11-20T08:03:13","modified_gmt":"2020-11-20T13:03:13","slug":"dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\/","title":{"rendered":"DermTech Enters Agreement with Blue Cross Blue Shield of Illinois"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p>\nDermTech Enters Agreement with Blue Cross Blue Shield of Illinois\n<\/p>\n<p>LA JOLLA, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nDermTech, Inc. (NASDAQ: DMTK) (\u201cDermTech\u201d), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it has entered into an agreement, effective November 3, 2020, with Blue Cross Blue Shield of Illinois for its Commercial PPO and Medicare Advantage membership.\n<\/p>\n<p>\nDermTech\u2019s PLA is the first non-invasive gene expression test for the early detection of melanoma. The PLA has a 99% negative predictive value (\u201cNPV\u201d), meaning there is a less than 1% probability of the PLA missing a melanoma when administered properly.\n<\/p>\n<p>\n\u201cWe are excited to announce that our test is now available to a segment of commercial and Medicare Advantage members. Our PLA test offers significant benefits in early melanoma detection and reduced biopsies of benign lesions while also reducing overall costs to the healthcare system,\u201d said Dan Visage, Senior Vice President of Payor Access.\n<\/p>\n<p>\nAbout DermTech:\n<\/p>\n<p>\nDermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech\u2019s mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech\u2019s investor relations site at: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.dermtech.com&amp;esheet=52332995&amp;newsitemid=20201120005177&amp;lan=en-US&amp;anchor=www.DermTech.com.&amp;index=1&amp;md5=8d19bb7ce97e082c939d24f528c87d4b\">www.DermTech.com.<\/a><\/p>\n<p>\nForward-Looking Statements:\n<\/p>\n<p>\nThis press release includes \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as \u201cexpect,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cbudget,\u201d \u201cforecast,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cbelieves,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, cost-effectiveness and commercialization of DermTech\u2019s products and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech\u2019s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech\u2019s tests; (4) the reimbursement of DermTech\u2019s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech\u2019s products; (6) DermTech\u2019s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech\u2019s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and\/or competitive factors; and (9) other risks and uncertainties included in (x) the \u201cRisk Factors\u201d section of the most recent Quarterly Report on Form 10\u2011Q filed by DermTech with the Securities and Exchange Commission (the \u201cSEC\u201d), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201120005177r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201120005177\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201120005177\/en\/<\/a><\/span><\/p>\n<p>\nSarah Dion<br \/>\n<br \/>VP Marketing<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:sdion@dermtech.com\">sdion@dermtech.com<br \/>\n<\/a><br \/>(858) 450-4222\n<\/p>\n<p><b>KEYWORDS:<\/b> California Illinois United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Insurance Oncology General Health Health Medical Devices Professional Services Genetics Other Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>DermTech Enters Agreement with Blue Cross Blue Shield of Illinois LA JOLLA, Calif.&#8211;(BUSINESS WIRE)&#8211; DermTech, Inc. (NASDAQ: DMTK) (\u201cDermTech\u201d), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it has entered into an agreement, effective November 3, 2020, with Blue Cross Blue Shield of Illinois for its Commercial PPO and Medicare Advantage membership. DermTech\u2019s PLA is the first non-invasive gene expression test for the early detection of melanoma. The PLA has a 99% negative predictive value (\u201cNPV\u201d), meaning there is a less than 1% probability of the PLA missing a melanoma when administered properly. \u201cWe are excited to announce that our test is now available to a segment of commercial and Medicare Advantage members. Our &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;DermTech Enters Agreement with Blue Cross Blue Shield of Illinois&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-385917","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>DermTech Enters Agreement with Blue Cross Blue Shield of Illinois - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DermTech Enters Agreement with Blue Cross Blue Shield of Illinois - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DermTech Enters Agreement with Blue Cross Blue Shield of Illinois LA JOLLA, Calif.&#8211;(BUSINESS WIRE)&#8211; DermTech, Inc. (NASDAQ: DMTK) (\u201cDermTech\u201d), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it has entered into an agreement, effective November 3, 2020, with Blue Cross Blue Shield of Illinois for its Commercial PPO and Medicare Advantage membership. DermTech\u2019s PLA is the first non-invasive gene expression test for the early detection of melanoma. The PLA has a 99% negative predictive value (\u201cNPV\u201d), meaning there is a less than 1% probability of the PLA missing a melanoma when administered properly. \u201cWe are excited to announce that our test is now available to a segment of commercial and Medicare Advantage members. Our &hellip; Continue reading &quot;DermTech Enters Agreement with Blue Cross Blue Shield of Illinois&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-20T13:03:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201120005177r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"DermTech Enters Agreement with Blue Cross Blue Shield of Illinois\",\"datePublished\":\"2020-11-20T13:03:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\\\/\"},\"wordCount\":708,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201120005177r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\\\/\",\"name\":\"DermTech Enters Agreement with Blue Cross Blue Shield of Illinois - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201120005177r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-11-20T13:03:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201120005177r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201120005177r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DermTech Enters Agreement with Blue Cross Blue Shield of Illinois\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DermTech Enters Agreement with Blue Cross Blue Shield of Illinois - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\/","og_locale":"en_US","og_type":"article","og_title":"DermTech Enters Agreement with Blue Cross Blue Shield of Illinois - Market Newsdesk","og_description":"DermTech Enters Agreement with Blue Cross Blue Shield of Illinois LA JOLLA, Calif.&#8211;(BUSINESS WIRE)&#8211; DermTech, Inc. (NASDAQ: DMTK) (\u201cDermTech\u201d), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it has entered into an agreement, effective November 3, 2020, with Blue Cross Blue Shield of Illinois for its Commercial PPO and Medicare Advantage membership. DermTech\u2019s PLA is the first non-invasive gene expression test for the early detection of melanoma. The PLA has a 99% negative predictive value (\u201cNPV\u201d), meaning there is a less than 1% probability of the PLA missing a melanoma when administered properly. \u201cWe are excited to announce that our test is now available to a segment of commercial and Medicare Advantage members. Our &hellip; Continue reading \"DermTech Enters Agreement with Blue Cross Blue Shield of Illinois\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-20T13:03:13+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201120005177r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"DermTech Enters Agreement with Blue Cross Blue Shield of Illinois","datePublished":"2020-11-20T13:03:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\/"},"wordCount":708,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201120005177r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\/","name":"DermTech Enters Agreement with Blue Cross Blue Shield of Illinois - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201120005177r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-11-20T13:03:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201120005177r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201120005177r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-enters-agreement-with-blue-cross-blue-shield-of-illinois\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"DermTech Enters Agreement with Blue Cross Blue Shield of Illinois"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/385917","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=385917"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/385917\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=385917"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=385917"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=385917"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}